Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2013British Journal of PharmacologyOpen Access

Therapeutic potential of histamine H4 receptor agonists in triple‐negative human breast cancer experimental model

View Full Paper
Ask AI
Bookmark
Share

Authors

DLDiego J. Martinel LamasConsejo Nacional de Investigaciones Científicas y TécnicasMCMáximo CrociConsejo Nacional de Investigaciones Científicas y TécnicasECEliana Carabajal

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lamas et al. (2013) studied this question.

synapsesocial.com/papers/6a6c9634a528af2d65c2868fhttps://doi.org/10.1111/bph.12137
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cancer Statistics, 20102010 · 12,621 citations
  2. 2The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis2011 · 80 citations
  3. 3Pharmacological characterization of the new histamine H4receptor agonist VUF 84302009 · 52 citations
  4. 4Cloning and characterization of dominant negative splice variants of the human histamine H4 receptor2008 · 65 citations